Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells by Diouf Barthelemy, Cheng Qing, Krynetskaia Natalia F, Yang Wenjian, Cheok Meyling, Pei Deqing, Fan Yiping, Cheng Cheng, Krynetskiy Evgeny Y, Geng Hui, Chen Siying, Thierfelder William E, Mullighan Charles G, Downing James R, Hsieh Peggy, Pui Ching-Hon, Relling Mary V, Evans William E in Nature medicine (2011).

[PMID: 21946537] PubMed


DNA mismatch repair enzymes (for example, MSH2) maintain genomic integrity, and their deficiency predisposes to several human cancers and to drug resistance. We found that leukemia cells from a substantial proportion of children (¿11%) with newly diagnosed acute lymphoblastic leukemia have low or undetectable MSH2 protein levels, despite abundant wild-type MSH2 mRNA. Leukemia cells with low levels of MSH2 contained partial or complete somatic deletions of one to four genes that regulate MSH2 degradation (FRAP1 (also known as MTOR), HERC1, PRKCZ and PIK3C2B); we also found these deletions in individuals with adult acute lymphoblastic leukemia (16%) and sporadic colorectal cancer (13.5%). Knockdown of these genes in human leukemia cells recapitulated the MSH2 protein deficiency by enhancing MSH2 degradation, leading to substantial reduction in DNA mismatch repair and increased resistance to thiopurines. These findings reveal a previously unrecognized mechanism whereby somatic deletions of genes regulating MSH2 degradation result in undetectable levels of MSH2 protein in leukemia cells, DNA mismatch repair deficiency and drug resistance.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.